N
NVCR
Novocure
10.58
-0.42-3.82%After Hours: 10.80 +0.22 +2.08%19:08 04/10 EDT
OPEN/PREV CLOSE11.00/11.00
TODAY RANGE10.53-11.00
VOL809.74K
MARKET CAP1.20B
52 WEEK RANGE9.82-20.06
AVG VOL (3M)1.88M
% TURNOVER0.71%
TURNOVER--
P/E (TTM)-8.6572
% RANGE4.32%
EPS(TTM)-1.2221
P/E(FORWARD)-7.1007
P/B3.496
BVPS3.027
DIVIDEND--
P/S1.816
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.08B
SHARES OUTSTANDING113.79M
NEXT EARNINGS04/20-05/05
FREE FLOAT102.16M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·14h ago
NovoCure Unifies Clinical And Innovation Roles As Market Discounts Persist
TipRanks·1d ago
NovoCure Expands Executive Role, Adjusts CMO Compensation
Simply Wall St·04/03 03:32
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer
Reuters·04/01 11:00
Novocure to report first-quarter results, host conference call and webcast
TipRanks·04/01 10:06
Zymeworks appoints Kristin Stafford as CFO
Reuters·04/01 10:00
Zymeworks appoints Kristin Stafford as CFO effective April 1, 2026
Simply Wall St·03/29 08:05
A Look At NovoCure (NVCR) Valuation After Extended Share Price Weakness
NASDAQ·03/27 12:10
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
Benzinga·03/26 15:19
NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer
Simply Wall St·03/26 14:07
Does Positive PANOVA-4 Data Alter the Bull Case For NovoCure’s TTFields Platform (NVCR)?
Seeking Alpha·03/26 12:53
4 stocks to watch on Thursday: MSFT, LITE, MARA, NVCR
Seeking Alpha·03/26 11:43
Novocure mid-stage trial for electric fields device succeeds in pancreatic cancer